Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60-days post-last cellfx treatment
Awards & highlights
Summary
This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.
Eligible Conditions
- Warts
- Warts Hand Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60-days post-last cellfx treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60-days post-last cellfx treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Verrucae Cleared
Secondary study objectives
Subject Satisfaction
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CellFX Treated WartExperimental Treatment1 Intervention
Treated wart with CellFX device intervention
Group II: Non-treated WartActive Control1 Intervention
Control wart for each enrolled subject without intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CellFX Device
2019
N/A
~70
Find a Location
Who is running the clinical trial?
Pulse Biosciences, Inc.Lead Sponsor
9 Previous Clinical Trials
730 Total Patients Enrolled
1 Trials studying Warts
150 Patients Enrolled for Warts
Richard Nuccitelli, PhDStudy ChairPulse Biosciences, Inc.
3 Previous Clinical Trials
282 Total Patients Enrolled
1 Trials studying Warts
150 Patients Enrolled for Warts
Share this study with friends
Copy Link
Messenger